22 November 2019 - Sunovion Pharmaceuticals today announced the resubmission of the new drug application to the U.S. FDA for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease in response to the 29 January 2019 complete response letter. 

This submission included information about intended packaging as well as additional analyses of clinical data.

Read Sunovion Pharmaceuticals press release